Trial Profile
The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms LUMEN
- 01 Feb 2024 Results assessing peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients, published in the Journal of Nuclear Medicine.
- 23 Sep 2022 Status changed from recruiting to completed.
- 26 Nov 2018 Planned End Date changed from 1 May 2018 to 1 Jan 2020.